Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Anaptysbio (ANAB) Receivables (2016 - 2025)

Historic Receivables for Anaptysbio (ANAB) over the last 11 years, with Q3 2025 value amounting to $75.7 million.

  • Anaptysbio's Receivables rose 52062.32% to $75.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $75.7 million, marking a year-over-year increase of 52062.32%. This contributed to the annual value of $40.8 million for FY2024, which is 49502.26% up from last year.
  • As of Q3 2025, Anaptysbio's Receivables stood at $75.7 million, which was up 52062.32% from $21.4 million recorded in Q2 2025.
  • Anaptysbio's Receivables' 5-year high stood at $75.7 million during Q3 2025, with a 5-year trough of $642000.0 in Q2 2021.
  • Moreover, its 5-year median value for Receivables was $3.2 million (2023), whereas its average is $10.9 million.
  • In the last 5 years, Anaptysbio's Receivables plummeted by 7506.0% in 2021 and then surged by 52062.32% in 2025.
  • Anaptysbio's Receivables (Quarter) stood at $876000.0 in 2021, then soared by 61.99% to $1.4 million in 2022, then surged by 382.8% to $6.9 million in 2023, then skyrocketed by 495.02% to $40.8 million in 2024, then soared by 85.66% to $75.7 million in 2025.
  • Its Receivables stands at $75.7 million for Q3 2025, versus $21.4 million for Q2 2025 and $17.9 million for Q1 2025.